It was reported that DNMT inhibitors induce a BRCAness phenotype through the downregulation of homologous recombination and NHEJ genes, thereby sensitizing non-small cell lung cancer cells to PARP inhibitors [44]. The gene discussed is DNMT1; the disease is non-small cell lung carcinoma.